Sugi Predict

Sugi Predict / Compounds / SCHEMBL1223701

SCHEMBL1223701

SCHEMBL1223701

O=C(O)c1cc(F)c2ncccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 5/20 0.47
▸ PSMD14 O00487 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MGAM O43451 1/20 0.44
▸ NAPRT Q6XQN6 1/20 0.43
▸ PDE4C Q08493 3/20 0.43
▸ PDE4D Q08499 3/20 0.43
▸ TRPM5 Q9NZQ8 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ PDE4B Q07343 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30419944 0.85 PARP1 (0.50) PDE4APSMD14ALDH1A1MEN1KMT2A
SCHEMBL29870758 0.85 KMT2A (0.44) PDE4APSMD14ALDH1A1MEN1KMT2A
SCHEMBL15703120 0.83 KDM4E (0.39) PDE4APSMD14ALDH1A1TRPM5LMNA
SCHEMBL28098162 0.81 PDE4A (0.43) PDE4AALDH1A1MEN1KMT2ATRPM5
SCHEMBL17442599 0.81 ALOX15 (0.58) PSMD14ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL68215 0.81 ALDH1A1 (0.54) PDE4APSMD14ALDH1A1MEN1KMT2A
SCHEMBL14305637 0.81 KDM4E (0.54) PDE4AALDH1A1LMNAALOX12L3MBTL1
SCHEMBL23166686 0.80 PTPN6 (0.50) PDE4APSMD14ALDH1A1MEN1KMT2A
SCHEMBL4204593 0.80 KDM4E (0.48) PDE4APSMD14ALDH1A1MEN1KMT2A
SCHEMBL21816233 0.80 PDE4A (0.47) PDE4APSMD14ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 — — CN claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
EP-3938340-B1 HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS COLLABORATIVE MEDICINAL DEV LLC (US) 2025-07-09 — — EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 — — CN disclosed
US-20240254110-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2024-08-01 — — US disclosed
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES (US) 2024-07-11 — — US disclosed
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES (US) 2024-07-11 — — US disclosed
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES (US) 2024-07-11 — — US disclosed
CN-118290350-A Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders 协同医药发展有限公司 2024-07-05 — — CN disclosed
WO-2019142053-A2 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS, INC. (BB) 2019-07-25 — — WO disclosed
US-20160289216-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-10-06 — — US disclosed
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 — — US disclosed
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 — — US disclosed
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 — — US disclosed
WO-2014066506-A2 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-05-01 — — WO disclosed
EP-2710119-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION Cleave Biosciences, Inc. (US) 2014-03-26 — — EP disclosed
WO-2012158435-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION ZHOU HAN-JIE (US) 2012-11-22 — — WO disclosed
US-20110033393-A1 Hydrazone Compounds and Their Use REDPOINT BIO CORPORATION 2011-02-10 — — US disclosed
WO-2010132615-A1 HYDRAZONE COMPOUNDS AND THEIR USE STEIN PHILIP (US) 2010-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION USP24, USP36, USP39 PDE4A 3261/4885PSMD14 7/4885ALDH1A1 4211/4885
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 PDE4A 1740/4885PSMD14 2059/4885ALDH1A1 3041/4885
US-20110033393-A1 Hydrazone Compounds and Their Use TRPM5, TRPV5, TRPM8 PDE4A 1972/4885PSMD14 4310/4885ALDH1A1 493/4885
US-20240254110-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 PDE4A 3331/4885PSMD14 2079/4885ALDH1A1 408/4885
US-20160289216-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 PDE4A 3858/4885PSMD14 1787/4885ALDH1A1 510/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PDE4A 840/4885PSMD14 2530/4885ALDH1A1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.